According to the World Health Organisation, self-administered, injectable contraception is among the new opportunities for self-care interventions, expanding women’s and girls’ access to sexual and reproductive health services. Recent research suggests that the doses of current self-injectable contraceptives using depot-medroxyprogesterone acetate (DMPA) are greater than necessary to effectively contracept for the product’s labelled duration of three months. Extending the reinjection interval to four months or longer would reduce long-term exposure to medroxyprogesterone acetate, risk of accumulation, and other dose-dependent side effects.
Together with our partner FHI360, Scope is conducting market research among current and potential contraceptive injectable users in Nigeria. We will assess the user acceptance of introducing a four- and six-month DMPA product to the market for self-injection as well as user perspectives on having multiple injectable products of different durations in the market. In addition, we will develop communication strategies and marketing messages to differentiate the new product from other similar products. Especially in resource-constrained settings, a longer reinjection interval would not only increase access to contraception but also reduce contraception costs for users and service delivery.
The rapid, qualitative market research study will be guided by human-centered design (HCD) and creative communication principles as well as include the use of participatory design methods. The study consists of a market assessment focusing on existing user preferences, mindsets, and behaviours to generate nuanced, rich qualitative data and insights; collaborative synthesis sprints to consolidate findings; and a participatory messaging ideation workshop for potential users to develop an effective communications strategy and connected marketing efforts.Back to our work